[{"NetIncomeLossConverted_2_Q2_USD":2868500000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":911600000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":910900000.0,"RevenuesConverted_1_Q2_USD":5499400000.0,"RevenuesConverted_2_Q2_USD":11359200000.0,"CommonStockDividendsPerShareDeclared_2_Q2_USD":0.74,"CommonStockDividendsPerShareDeclared_1_Q2_USD":0.74,"Assets_0_Q2_USD":41967000000.0,"StockholdersEquity_0_Q2_USD":4092900000.0,"EarningsPerShareDiluted_2_Q2_USD":3.15,"EarningsPerShareDiluted_1_Q2_USD":1.55,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":2877800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":907700000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":907200000.0,"StockholdersEquityConverted_0_Q2_USD":4272000000.0,"NetIncomeLossConverted_1_Q2_USD":1412000000.0,"EarningsPerShareBasic_1_Q2_USD":1.56,"EarningsPerShareBasic_2_Q2_USD":3.16,"Ticker":"LLY","CIK":"59478","name":"ELI LILLY & CO","OfficialName":"Eli Lilly and Company Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"282857000000.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"SP500","filed":"20200731"}]